Retatrutide 5mg “Triple G”

Retatrutide – World’s 1st Triple Agonist Peptide “Triple G”

Clinical Study Findings

At 48 weeks, the least-squares mean percentage change in body weight was:

• Placebo Group: −2.1%
• 1 mg Retatrutide: −8.7%
• 4 mg Retatrutide (combined): −17.1%
• 8 mg Retatrutide (combined): −22.8%
• 12 mg Retatrutide: −24.2%

Source: NEJM Study

Research Reference

Jastreboff A, Kaplan L, Frías J, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972

Additional Resources

• Health News: Retatrutide – A Powerful New Weight Loss and Diabetes Drug
• Pharmaceutical Technology: Eli Lilly’s Retatrutide for Weight Loss
• Medscape Article on Retatrutide

Introduction

Over the past few years, scientists have explored innovative approaches to tackling obesity as a global health challenge. Among these, triple agonist peptides have shown promising potential in weight loss research due to their demonstrated efficacy.

What is Retatrutide?

Retatrutide (LY3437943) is a triple agonist peptide that activates three key receptors in the body, all of which play a crucial role in metabolism and appetite regulation. By targeting these receptors simultaneously, Retatrutide aims to create a synergistic and comprehensive weight loss effect.

How Triple Agonist Peptides Work

These peptides target the following three receptors:

1. Melanocortin 4 Receptor (MC4R):
   • Regulates appetite and energy expenditure
   • Activation leads to reduced food intake and increased metabolism
2. Glucagon-Like Peptide-1 Receptor (GLP-1R):
   • Maintains glucose levels and promotes satiety
   • Improves insulin sensitivity and reduces food cravings
3. Gastric Inhibitory Peptide Receptor (GIPR):
   • Regulates insulin release and lipid metabolism
   • Enhances glucose metabolism and promotes fat utilization

The Power of Triple Agonist Peptides

The simultaneous activation of these receptors results in a unique and potent impact on weight management compared to single or dual-receptor agonists. Preclinical studies have shown:

• Significant body weight reduction
• Improved metabolic parameters
• Altered food intake patterns

Potential Benefits Beyond Weight Loss

Triple agonist peptides, like Retatrutide, may offer a comprehensive approach to weight management by addressing multiple metabolic dysfunctions. In addition to aiding in weight loss, these peptides have the potential to:

• Improve overall metabolic health
• Regulate glucose levels more effectively
• Enhance insulin sensitivity

Important Product Information

Products have undergone regular testing by a 3rd party DEA-certified laboratory and contain no known harmful ingredients for humans. This product should only be handled by licensed, qualified professionals.

Disclaimer: The statements made within this website have not been evaluated by the U.S. Food and Drug Administration (FDA).